Schwind PresbyMAX treats presbyopia with excimer surgery

Article

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.

In contrast to other methods of treating presbyopia, PresbyMAX delivers bi-aspheric multifocal ablation profiles. Bi-aspheric refers to aspheric optimisation of the central corneal area for near vision and the midperipheral cornea for far vision of each patient eye. Near vision of presbyopic patients, even with additional visual defects like distance refraction and high-order aberrations, is significantly improved, providing sharper vision without the need for spectacles.

The software was developed by Schwind in cooperation with VISSUM under the direction of editorial advisory board member, Prof. Jorge Alio, Spain, and the OCIVIS group from the University of Alicante. He said: “The central development goal of PresbyMAX was to provide the first systematic and scientifically based approach for the correction of presbyopia with excimer laser surgery.”

Similar to multifocal contact lenses or refractive multifocal IOLs, PresbyMAX creates a multifocal corneal surface. Bi-aspheric multifocal ablation profiles are optimised using a predictive model based on a light propagation algorithm.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.